January 24, 2007 - Popular drugs used to treat erectile dysfunction ? Viagra, Levitra and Cialis ? are safe and effective for men with diabetes, a new review has found.

The introduction of the medications known as phosphodiesterase type 5 (PDE-5) inhibitors to the market has changed the way physicians manage their patients with erectile dysfunction. The drugs have been shown to be quite effective in treating the condition in the general population and the number of men requesting them has soared in recent years.

The aim of the systematic review, however, was to determine whether PDE-5 inhibitors such as sildenafil (Viagra), vardenafil (Levitra) and tadalafil (Cialis) are also a safe and effective option for men with diabetes. Although diabetes can causes a variety of other chronic complications, such as heart disease and high blood pressure, PDE-5 inhibitors were shown not to cause many adverse reactions in this group.

At the end of the studies, men who took PDE-5 inhibitors showed improvements on all measures of erectile function, with an average difference of 26.7 percent more successful intercourse attempts compared to placebo groups.

The review appears in the current issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates research in all aspects of health care. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing trials on a topic.

The results of our meta-analysis are not surprising, but give strength to the general notion that this class of drugs is efficient and safe for this specific wide population, said lead author Moshe Vardi, M.D., with the internal medicine division at Lady Davis Carmel Medical Center in Israel.

The Cochrane reviewers analyzed eight studies that compared the effectiveness of the three PDE-5 medications to placebo. A total of 1,759 men were recruited ? with roughly half randomized to receive PDE-5 inhibitor therapy and the rest to the placebo group. Overall, 80 percent of the participants had type 2 diabetes and the others had type 1 diabetes.

Source::
http://www.seniorjournal.com/NEWS